Wellorithm Review: Is It Legit?

Availability scores 8.69 out of 10 and carries a weight of 5. The brand's own site says it serves 49 states and cannot provide services in Louisiana. Its terms page states something different: services in all 50 states plus D.C. Two of the brand's own pages disagree on where it operates. We print the contradiction rather than resolve it. Shipping is stated free on every program. No shipping-speed claim is stored as its own record in our capture. Not published is an answer we print here too: a reader in an excluded state finds out at sign-up, not on the program's pages. A single, consistent states list would move this dimension and settle the contradiction.

We store four verbatim claims from the brand, captured on Aug 30, 2026. On the program, the site reads: "The program includes consultations, prescriptions for weight-loss medications (such as semaglutide or tirzepatide), and a monthly shipment of compounded medication." On eligibility, it states: "To qualify, users must be new, complete an intake report, follow prescribed medication doses for 16 weeks, and not have been on other weight-loss medications in the prior year." On its role, it states that the "platform functions as a facilitator, not a medical provider". These are program and eligibility claims, not results claims. Four claims across three captured pages is a thin harvest, and that thinness is one reason our published confidence is low.

Traceability scores 5.8 out of 10. The brand names no pharmacy in our record; the pharmacy field is empty. Pharmacy type is not published, and an unpublished type scores 3 out of 10 on that sub-check. With no pharmacy name to match, we hold no facility in the FDA register and no inspection record — and never inspected is not a passed inspection; that check drops out of the denominator instead of scoring. The programs do name a molecule and a form: semaglutide and tirzepatide, each offered as an injection and as an oral tablet. The brand states plainly that it ships "a monthly shipment of compounded medication." In our view a program that sells compounded medication should name the pharmacy that fills it. Naming the pharmacy and stating its category would move this dimension furthest, and it is the single change within the brand's control that would help the total.

Price transparency scores 8.83 out of 10 and carries a weight of 20. Our record holds eight programs. Compounded semaglutide lists at $147 a month in both injection and oral form, and compounded tirzepatide at $249 in both forms. Brand-name programs list higher: Wegovy at $899, Zepbound and Ozempic at $1199, and Mounjaro at $1399. Consult and shipping are stated free on every program. The brand advertises $100 off the first month across plans. None of these prices carries a public-page source in our record; the price source reads none on all eight. On our re-read every one of the eight came back unparsed. A fact we could not read never scores against the brand. Unparsed checks drop out of the arithmetic and lower our confidence instead. A readable pricing page on the brand's own domain that names each molecule and its price would move this dimension.

Cost and value scores 7 out of 10 and carries a weight of 15. Among the 32 live compounded programs we track, Wellorithm's entry price ranks 13. Its $147 entry month sits just under the cohort median of $159.50, and three months at the entry rate total $441. The disclosed fee load on top is $0: consult and shipping are both stated free. For context, CMS lists the acquisition cost of one Wegovy 1.7 mg pen package at $870.80. That is a pharmacy acquisition cost. It is not what a patient pays, and it never enters the score. The entry price is what earns the sub-score, and it moves only with the cohort or with a lower published price. In our view the pricing is competitive for a compounded program; the value case is real and the score reflects it.

Clinical access scores 7.2 out of 10. The brand describes 24/7 access to a dedicated team, unlimited appointments and messaging, and board-certified obesity specialists and medical consultants. It states that it "connects you with board-certified obesity specialists and medical consultants to develop tailored plans." That description names a specialty but no individual clinician and no licensure line, so the prescriber sub-check does not reach full marks. The contact model is stated. A time to first contact is not published in our record. The how-it-works page we captured held 63 characters of readable text, so our read of the intake flow is thin. In our view a description of a team is not the same as a named clinical lead. A named prescriber, a stated licensure and a published wait time would each move this dimension.

Safety and enforcement scores 10 out of 10 and carries a weight of 20. We hold no FDA warning letter against the brand, no letter against any pharmacy it names, and no open flag of any kind. The brand holds LegitScript certification in our record. The absence of a letter is not a clearance. It means the registers we check are clean as of Aug 30, 2026, and nothing more. This dimension can only fall from here. A new letter, a new flag or a facility action would move it down on the day we ingest it; no disclosure can push it above 10.

Terms score 10 out of 10 and carry a weight of 10. All programs state cancel anytime, and none carries a minimum commitment. The brand publishes a weight-loss guarantee that ties a possible refund of up to four months of fees to a 16-week medication course, dose adherence, and no other weight-loss medication in the prior year. The terms page we captured is readable, at 8,731 characters. Every sub-check in this dimension scores 10 out of 10, so the arithmetic needs no correction and we apply no modifier. In our view the guarantee is real but conditional; a reader should note the strict eligibility before counting on it. Nothing here would move the score up; it already sits at the ceiling. A minimum commitment or a narrowed refund window would move it down.

These are the reviews Wellorithm chose to put on its own site; this site does not collect independent reviews. Our record holds no testimonial claim from the brand, and no reviews page is among our captures. So this section prints none. A paraphrased testimonial inside quotation marks would be a fabricated quote, and preventing that is the point of our evidence layer. Not captured is an answer we print as well. When a later crawl stores testimonial claims from the brand's own site, they will appear here verbatim, each cited, and never aggregated into a number.

Nothing precedes this analysis. It is the first we publish for Wellorithm, so there is no earlier text and no earlier published score to diff against. The baseline is 8.2 out of 10 at methodology v1, computed on Aug 30, 2026. Two threads stand out for the next run: the states contradiction between the two pages, and a pricing page our crawler can read so the eight programs stop resting on stored figures. From the next weekly run onward, this section reports price drift, a changed pricing page, claims gained or lost, and any new flag — and it stays off the page when nothing moved.